Mediaboss Marketing

PRESS RELEASE: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

DGAP-News: Evotec AG / Key word(s): Miscellaneous Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

10.12.2013 / 07:29

=--------------------------------------------------------------------

Hamburg, Germany - 10 December 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of EUR 4.0 m to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec's overall strategy of building up a pipeline of assets of which we have interest in future upside.'

ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE In 2004, Evotec entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim to jointly identify and develop pre-clinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases. In 2009, the collaboration was extended for an additional four years and the scope expanded to include oncology targets. Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified. In return, Evotec receives ongoing research payments and pre-clinical milestones. Furthermore, the contract provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG: Gabriele Hansen, Head of Corporate Communications, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

Follow this link:
PRESS RELEASE: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

WordPress-Post Formats
WordPress-Post Formats.

By: word Press

View original post here:
WordPress-Post Formats - Video

WordPress-Importing Text
WordPress-Importing Text.

By: word Press

Follow this link:
WordPress-Importing Text - Video

PRESS RELEASE: MOLOGEN AG: Treatment phase of safety trial with MGN1703 in the U.S. completed

DGAP-News: MOLOGEN AG / Key word(s): Study MOLOGEN AG: Treatment phase of safety trial with MGN1703 in the U.S. completed

09.12.2013 / 08:01

=--------------------------------------------------------------------

MOLOGEN AG: Treatment phase of safety trial with MGN1703 in the U.S. completed

Berlin, December 9, 2013 - The treatment phase of the clinical trial phase I for MGN1703 in the U.S. was finished according to plan. In terms of safety and tolerability no significant clinical events were observed to date. The study will be completed on schedule until year-end. MOLOGEN expects that first results will become available in early 2014.

The placebo-controlled, double-blind study evaluates the cardiac and general safety as well as pharmacodynamics of MGN1703 in healthy volunteers. The trial will add to the already comprehensive data package on tolerability and mechanism of action and forms the basis for the further development of MGN1703 in the U.S. until market approval.

MGN1703 has already successfully completed a phase II study in metastatic colorectal cancer (mCRC) in Europe. MOLOGEN is currently preparing a pivotal study in mCRC. In addition a randomized controlled trial to assess the efficacy of MGN1703 in small cell lung cancer has already been applied for to extend the scope of MGN1703.

About MGN1703 MGN1703 is based on dSLIM(R) ('double Stem Loop Immunomodulator'), an innovative DNA-based TLR9 agonist developed by MOLOGEN. dSLIM(R) activates the immune system against tumor-associated antigens by targeting various receptors on certain immune cells, primarily TLR9. Tumor-associated antigens (TAA) are released by cancer cells as a result of chemotherapy and radiation therapy. Once activated by dSLIM(R), the immune system is able to overcome its fatal tolerance toward cancer cells and TAA and attacks them selectively. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.

About MOLOGEN AG MOLOGEN AG is a publicly listed biotechnology company headquartered in Berlin and specializes in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and lung cancer. The cell-based cancer therapy MGN1601 for the treatment of renal cancer is also currently at the stage of clinical development. With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies. MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.

Read the original post:
PRESS RELEASE: MOLOGEN AG: Treatment phase of safety trial with MGN1703 in the U.S. completed

PRESS RELEASE: Schweizer Electronic AG: Elekonta and SCHWEIZER agree on partnership

DGAP-News: Schweizer Electronic AG / Key word(s): Alliance Schweizer Electronic AG: Elekonta and SCHWEIZER agree on partnership

09.12.2013 / 10:04

=--------------------------------------------------------------------

Schramberg/Gerlingen, December 9, 2013 - Elekonta Marek GmbH & Co. KG and Schweizer Electronic AG have concluded an agreement on a cooperation in the prototype segment for innovative Printed Circuit Board (PCB) solutions.

The increasing trend towards high tech and innovative products in the European PCB market forms the basis of this collaboration. It is a constant challenge for suppliers to provide customers with adequate technology samples in high quality which are suitable for subsequent serial production.

Via the cooperation with SCHWEIZER, Elekonta, a company focussing on prototype manufacturing of PCBs, expands its service for existing customers. Following the successful execution of prototypes, these customers will then have the option of having SCHWEIZER produce mid-size and high-volume series. SCHWEIZER's customers, on the other hand, will be offered a second source for the production of samples via Elekonta.

In their collaboration and for the benefit of their customers, the partners will concentrate on the area of new technologies, the related exchange of trends and the multiplying factor connected to it. Initially, Elekonta and SCHWEIZER will focus on HDI, thick copper, HF and impedance-controlled PCBs.

'The new partnership will ensure that technology samples can later on be produced in adequate quality and reliability in high volumes' says Christian Rssle, Vice President Sales & Marketing at SCHWEIZER.

And Lars Presche, Managing Director with Elekonta Marek, adds: 'Via this cooperation we would like to generate for our customers an additional value-add in the product life cycle and to counter the continuously growing trade business'.

Read the rest here:
PRESS RELEASE: Schweizer Electronic AG: Elekonta and SCHWEIZER agree on partnership